TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

↓ Download CSV

CIK 0000818686 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated L3
  • Fiscal year ends Dec 31

In fiscal 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD reported revenue of $17.26B, up 4.3% from the prior year. The company was profitable, with a net margin of 8.2% and a gross margin of 51.8%. It held $40.75B in total assets against $32.83B in total liabilities.

Key ratios (FY2025)

51.8%
Gross margin
12.5%
Operating margin
8.2%
Net margin
17.8%
Return on equity
+4.3%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$17.26B$16.54B$15.85B$14.93B$15.88B$16.66B$16.89B$18.27B$21.85B$21.90B
Cost of Revenue$8.32B$8.48B$8.20B$7.95B$8.28B$8.93B$9.35B$9.97B$11.24B$10.25B
Gross Profit$8.94B$8.06B$7.64B$6.97B$7.59B$7.73B$7.54B$8.30B$10.62B$11.65B
Operating Income$2.16B-$303.00M$433.00M-$2.20B$1.72B-$3.57B-$443.00M-$1.64B-$17.48B$2.15B
Net Income$1.41B-$1.64B-$559.00M-$2.45B$417.00M-$3.99B-$999.00M-$2.15B-$16.27B$329.00M
EPS (Diluted)$1.21$-1.45$-0.50$-2.20$0.38$-3.64$-0.91$-2.35$-16.26$0.07
Total Assets$40.75B$39.33B$43.48B$44.01B$47.67B$50.64B$57.47B$60.68B$70.61B
Total Liabilities$32.83B$33.61B$35.35B$35.41B$36.42B$39.58B$42.41B$44.89B$51.87B
Shareholders' Equity$7.91B$5.38B$8.13B$8.60B$11.24B$11.06B$15.06B$15.79B$18.75B$34.99B
Cash & Equivalents$3.56B$3.30B$3.23B$2.80B$2.17B$2.18B$1.98B$1.78B$963.00M
Operating Cash Flow$1.65B$1.25B$1.37B$1.59B$798.00M$1.22B$748.00M$2.45B$2.23B$3.89B
Capital Expenditures$501.00M$498.00M$526.00M$548.00M$562.00M
Shares Outstanding1.16B1.13B1.12B1.11B1.11B1.09B1.09B1.02B1.02B961
Dividends Per Share$0.00$0.00$0.85$1.36